Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Telix Pharmaceuticals ( (AU:TLX) ) just unveiled an update.
Telix Pharmaceuticals Limited has updated its Securities Dealing Policy effective from December 11, 2025, in compliance with ASX Listing Rule 12.10. This update reflects the company’s ongoing commitment to regulatory compliance and may impact its operations by ensuring transparency and integrity in securities dealings, potentially affecting investor confidence and stakeholder engagement.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$28.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, the company operates internationally, including in the United States, United Kingdom, Brazil, Canada, Europe, and Japan. Telix aims to address significant unmet medical needs in oncology and rare diseases.
YTD Price Performance: -44.17%
Average Trading Volume: 1,902,859
Technical Sentiment Signal: Sell
Current Market Cap: A$4.65B
See more data about TLX stock on TipRanks’ Stock Analysis page.